Belgian biotech company will use funding to start first-in-human clinical study for lead drug candidate in lung cancer Liege, Belgium, January 19, 2023 – DeuterOncology, a clinical-stage drug development company, today announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from his.
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors:.
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study EP4R antagonist is Domain Therapeutics' first fully-owned immuno-oncology